Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Impact of oral silymarin on virus- and non-virus-specific T-cell responses in chronic hepatitis C infection.

Adeyemo O, Doi H, Rajender Reddy K, Kaplan DE.

J Viral Hepat. 2013 Jul;20(7):453-62. doi: 10.1111/jvh.12050. Epub 2013 Apr 12.

2.

Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period.

MariƱo Z, Crespo G, D'Amato M, Brambilla N, Giacovelli G, Rovati L, Costa J, Navasa M, Forns X.

J Hepatol. 2013 Mar;58(3):415-20. doi: 10.1016/j.jhep.2012.09.034. Epub 2012 Oct 11.

PMID:
23063567
3.

Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial.

Fried MW, Navarro VJ, Afdhal N, Belle SH, Wahed AS, Hawke RL, Doo E, Meyers CM, Reddy KR; Silymarin in NASH and C Hepatitis (SyNCH) Study Group..

JAMA. 2012 Jul 18;308(3):274-82. doi: 10.1001/jama.2012.8265.

4.
5.

Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C.

Reddy KR, Belle SH, Fried MW, Afdhal N, Navarro VJ, Hawke RL, Wahed AS, Doo E, Meyers CM; SyNCH Study Group..

Clin Trials. 2012 Feb;9(1):102-12. doi: 10.1177/1740774511427064. Epub 2011 Nov 4.

6.

Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C.

Schrieber SJ, Hawke RL, Wen Z, Smith PC, Reddy KR, Wahed AS, Belle SH, Afdhal NH, Navarro VJ, Meyers CM, Doo E, Fried MW.

Drug Metab Dispos. 2011 Dec;39(12):2182-90. doi: 10.1124/dmd.111.040212. Epub 2011 Aug 24.

7.

Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C.

Hawke RL, Schrieber SJ, Soule TA, Wen Z, Smith PC, Reddy KR, Wahed AS, Belle SH, Afdhal NH, Navarro VJ, Berman J, Liu QY, Doo E, Fried MW; SyNCH Trial Group..

J Clin Pharmacol. 2010 Apr;50(4):434-49. doi: 10.1177/0091270009347475. Epub 2009 Oct 19.

8.

Silybin treatment is associated with reduction in serum ferritin in patients with chronic hepatitis C.

Bares JM, Berger J, Nelson JE, Messner DJ, Schildt S, Standish LJ, Kowdley KV.

J Clin Gastroenterol. 2008 Sep;42(8):937-44. doi: 10.1097/MCG.0b013e31815cff36.

PMID:
18458640

Supplemental Content

Loading ...
Support Center